12:00 AM
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Deals

Portola, Bayer, J&J deal

The companies partnered to conduct a Phase II proof-of-concept trial to evaluate the ability of Portola's PRT4445 to reverse the anticoagulation activity of Xarelto rivaroxaban in emergency situations. Portola is responsible for conducting the trial. J&J's Janssen Pharmaceuticals Inc. subsidiary and Bayer will make an undisclosed upfront cash payment to Portola and will provide development and regulatory guidance for the trial, which is slated to be completed...

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >